Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience


UYSAL A., AKAD SOYER N., Ozkan M., ŞAHİN F. , VURAL F. , TÖBÜ M. , et al.

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.48, ss.80-83, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 48 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3906/sag-1611-97
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Sayfa Sayısı: ss.80-83

Özet

Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.